论文部分内容阅读
目的 :探讨过氧化物酶增殖体激活的受体γ(PPAR γ)在肾癌细胞中的表达及PPAR γ配体曲格列酮对肾癌细胞凋亡的影响。方法 :通过RT -PCR、Westernblot方法 ,从mRNA及蛋白水平检测PPAR γ在肾癌细胞株786 O、A4 98及正常肾来源的细胞株HK 2、HMCC中的表达 ,DNA梯度电泳、荧光显微镜观察曲格列酮诱导肾癌细胞凋亡的现象 ,Westernblot检测Bcl 2、Bax蛋白在肾癌细胞凋亡过程中的变化。结果 :PPAR γ在肾癌细胞株中的表达高于正常肾来源的细胞株 ,5 0 μmol/L曲格列酮可以诱导肾癌细胞凋亡 ,伴随有Bcl 2表达的减少及Bax表达的增加。结论 :曲格列酮可以诱导肾癌细胞的凋亡 ,PPAR γ配体有可能成为新的治疗肾细胞癌的药物
Objective: To investigate the expression of peroxisome proliferator activated receptor γ (PPARγ) in renal cell carcinoma and the effect of PPARγ ligand troglitazone on apoptosis of renal cell carcinoma. Methods: The mRNA and protein levels of PPARγ were detected by RT-PCR and Western blotting. The expression of PPARγ in human renal cell carcinoma cell line 786 O, A4 98 and normal kidney derived cell lines HK 2 and HMCC were detected by DNA ladder and fluorescence microscopy Troglitazone induced the apoptosis of renal cell carcinoma cells. The changes of Bcl-2 and Bax protein in renal cell carcinoma cells were detected by Western blot. Results: The expression of PPARγ in renal cell carcinoma was higher than that in normal renal cells. Troglitazone at a concentration of 50 μmol / L could induce the apoptosis of renal cell carcinoma with the decrease of Bcl 2 expression and the increase of Bax expression . CONCLUSION: Troglitazone induces apoptosis in human renal cell carcinoma, and PPARγ ligand may be a new drug for the treatment of renal cell carcinoma